Pancreatic Surgical Unit, Department of General and Vascular Surgery, Pederzoli Hospital, Peschiera del Garda, Verona, Italy.
Unit of Pancreatic Surgery, University of Verona Hospital Trust, Verona, Italy.
Ann Surg Oncol. 2022 Dec;29(13):8503-8510. doi: 10.1245/s10434-022-12385-4. Epub 2022 Aug 17.
Resection of initially oligometastatic pancreatic ductal adenocarcinoma (PDAC) following response to first-line chemotherapy is controversial. We herein updated a previous case series to investigate the oncologic outcomes and preoperative factors that could drive the decision-making process.
This retrospective analysis was limited to patients with liver-only synchronous metastases who experienced complete regression of the metastatic component and underwent pancreatectomy between October 2008 and July 2020 at two high-volume institutions. Clinical-pathologic variables were captured, and inflammation-based prognostic scores were calculated. Recurrence and survival analyses were performed using standard statistical methods.
Overall, 52 patients were included. FOLFIRINOX was the most employed chemotherapy regimen (63.5%). Post-treatment tumor size, serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) were significantly decreased relative to baseline evaluation. The median time from diagnosis to pancreatectomy was 10.2 months, while the median time from chemotherapy completion to pancreatectomy was 2 months. Major postoperative complications occurred in 26.9% of patients, while postoperative mortality was nil. The median disease-free survival (DFS) and overall survival (OS) from pancreatectomy were 16.5 and 23.0 months, respectively, and the median OS from diagnosis was 37.2 months. At multivariable analysis, vascular resection, operative time, prognostic nutrition index (PNI) and neutrophil-to-lymphocyte ratio (NLR) were associated with OS. Operative time, platelet × neutrophil/lymphocyte count (SII), and PNI were associated with DFS.
We confirm promising outcomes of selected patients who underwent pancreatectomy following downstaging of liver metastases. The absence of vascular involvement of the primary tumor, good nutritional status, and low inflammatory index scores could be useful to select candidates for resection.
在一线化疗后对最初寡转移的胰腺导管腺癌(PDAC)进行切除术存在争议。我们在此更新了以前的病例系列研究,以调查可推动决策过程的肿瘤学结果和术前因素。
本回顾性分析仅限于仅肝同步转移的患者,这些患者在 2008 年 10 月至 2020 年 7 月期间在两个大容量机构经历了转移性成分的完全消退并接受了胰腺切除术。收集了临床病理变量,并计算了炎症为基础的预后评分。使用标准统计方法进行复发和生存分析。
总体而言,纳入了 52 例患者。FOLFIRINOX 是最常用的化疗方案(63.5%)。与基线评估相比,治疗后肿瘤大小、血清肿瘤标志物(CA)19-9 和癌胚抗原(CEA)显著降低。从诊断到胰腺切除术的中位时间为 10.2 个月,而从化疗完成到胰腺切除术的中位时间为 2 个月。26.9%的患者发生重大术后并发症,无术后死亡。从胰腺切除术开始的中位无病生存期(DFS)和总生存期(OS)分别为 16.5 和 23.0 个月,从诊断开始的中位 OS 为 37.2 个月。在多变量分析中,血管切除术、手术时间、预后营养指数(PNI)和中性粒细胞与淋巴细胞比值(NLR)与 OS 相关。手术时间、血小板×中性粒细胞/淋巴细胞计数(SII)和 PNI 与 DFS 相关。
我们确认了经过肝转移降期治疗后接受胰腺切除术的选定患者的有希望的结果。原发性肿瘤无血管受累、良好的营养状况和低炎症指数评分可能有助于选择适合手术的患者。